Observational Cohort Study of Bevacizumab Intravenous Injection in the Treatment of Early and Middle Stage of Knee Osteoarthritis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100049278

Enrollment

Unknown

Registered

2021-07-29

Start date

2021-07-30

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

Therapy group:Bevacizumab intravenously

Control group:None

Eligibility

Sex/Gender

All

Age

50 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients between the ages of 50-65 years; 2. Patients with early and mid-stage knee osteoarthritis who can receive basic treatment; 3. Patients with cartilage injury grade 3 and below; 4. Patients with fewer bowel cancer complications; 5. BMI greater than 18 and less than 28.

Exclusion criteria

Exclusion criteria: 1. Patients whose cancer has evidence of metastases to the extremities. 2. Patients with severe neurological and psychiatric diseases. 3. Suspect or have a history of alcohol or drug abuse.

Design outcomes

Primary

Measure	Time frame
WOMAC knee function score;	—

Countries

China

Contacts

Public ContactLi Wei

Peking University Shenzhen Hospital

lwjnu2003@126.com+86 15013457710

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026